Bicycle Therapeutics Ltd (BCYC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bicycle Therapeutics Ltd (BCYC) has a cash flow conversion efficiency ratio of -0.115x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-71.17 Million) by net assets ($618.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BCYC equity financing ratio to measure how much of total assets are equity-financed.
Bicycle Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Bicycle Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BCYC cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Bicycle Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bicycle Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Meridian Bank
NASDAQ:MRBK
|
-0.030x |
|
Golden Ventures Leasehold Real Estate Investment Trust
BK:GVREIT
|
0.026x |
|
Peninsula Group Ltd
TA:PEN
|
-0.033x |
|
Acrow Ltd
AU:ACF
|
0.085x |
|
Vef AB
ST:VEFAB
|
-0.001x |
|
Pitanium Ltd
NASDAQ:PTNM
|
-0.006x |
|
Kepler Weber S.A
SA:KEPL3
|
0.071x |
|
Z Squared Inc.
NASDAQ:ZSQR
|
-0.095x |
Annual Cash Flow Conversion Efficiency for Bicycle Therapeutics Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Bicycle Therapeutics Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Bicycle Therapeutics Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $793.06 Million | $-164.72 Million | -0.208x | -27.08% |
| 2023-12-31 | $370.93 Million | $-60.63 Million | -0.163x | +48.60% |
| 2022-12-31 | $270.78 Million | $-86.11 Million | -0.318x | -644.30% |
| 2021-12-31 | $346.25 Million | $-14.79 Million | -0.043x | +77.07% |
| 2020-12-31 | $95.46 Million | $-17.79 Million | -0.186x | +39.30% |
| 2019-12-31 | $93.20 Million | $-28.61 Million | -0.307x | -182.21% |
| 2018-12-31 | $-69.83 Million | $-26.08 Million | 0.373x | +1145.36% |
| 2017-12-31 | $-47.18 Million | $-1.42 Million | 0.030x | +102.14% |
| 2016-12-31 | $8.02 Million | $-11.27 Million | -1.404x | -- |
About Bicycle Therapeutics Ltd
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT552… Read more